1. Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma 
Ho-Young Yhim, Jin Seok Kim, Yeung-Chul Mun, Joon Ho Moon, Yee Soo Chae, Yong Park, Jae-Cheol Jo, Seok Jin Kim, Dok Hyun Yoon, June-Won Cheong, Jae-Yong Kwak, Je-Jung Lee, Won Seog Kim, Cheolwon Suh, Deok-Hwan Yang 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 9, Pages (September 2015)
DOI: /j.bbmt
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Survival outcomes according to Ann Arbor stage. The limited disease group had significantly longer (A) PFS and (B) OS rates than the advanced disease group.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
PFS in the (A and B) limited disease group and (C and D) advanced disease group. Comparison according to the (A) NKPI and (B) radiotherapy to the primary lesion in the limited disease group showed that a low-risk NKPI and combined chemotherapy–radiotherapy were associated with significantly longer PFS rates than a high-risk NKPI and chemotherapy alone, respectively. When we compared PFS in patients with advanced disease according to (C) pretransplant response and (D) primary chemotherapy, pretransplant CR achievement and non–anthracycline-based primary chemotherapy were associated with significantly better PFS than pretransplant PR and anthracycline-based chemotherapy, respectively.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions